Saturday 17 October 2026
Export CALC’s income statement to Excel — free account
CalciMedica Inc.
CALC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 12.5%, free cash flow grew 31.4% and total debt rose 8.24%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.07
0.01
−0.93%
Follow CALC
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 8.75 | 10.25 | 7.10 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 42.95 | 41.90 | 36.00 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 24 | 31 | 27 | 8 | 14 | 14 | 16 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (28) | (37) | (28) | (36) | (8) | (34) | (14) | (30) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | (28) | (37) | (28) | (36) | (8) | (34) | (14) | (30) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (1,566.00) | (1,964.87) | (367.64) | (118.34) | (116.21) | (38.30) | (6.10) | (9.85) | |||||
| Cash flow | — | — | (1,558.89) | (1,660.37) | (339.30) | (104.06) | (716.89) | (28.68) | (9.40) | (7.05) | |||||
| Capex | — | — | (80.72) | (32.18) | (10.83) | (1.61) | (0.24) | (0.09) | 0.00 | (0.01) | |||||
| Free cash flow | — | — | (1,639.61) | (1,692.55) | (350.13) | (105.68) | (717.13) | (28.76) | (9.41) | (7.06) | |||||
| Book value | — | — | (3,690.17) | (5,476.28) | 1,003.03 | 214.81 | (4,347.80) | 9.09 | 6.41 | (2.21) | |||||
| Shares, m | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (28) | (31) | (32) | (31) | (12) | (26) | (21) | (21) | ||||
| Capex | — | — | (1) | (1) | (1) | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | (30) | (32) | (33) | (32) | (12) | (26) | (21) | (21) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 8 | 24 | 92 | 63 | (3) | 8 | 16 | 10 | ||||
| Total debt | — | — | 79 | 131 | — | — | 5 | — | — | 10 | |||||
| Net debt | — | — | 66 | 95 | (95) | (64) | 4 | (11) | (19) | (3) | |||||
| Shareholders’ equity | — | — | (67) | (103) | 95 | 65 | (71) | 8 | 14 | (7) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (111.83) | (150.81) | (48.75) | (41.92) | (25.24) | (442.35) | (85.68) | (177.10) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (1,660.52) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 38.52 | 51.95 | 850.15 | (44.83) | 291.10 | 108.82 | (121.42) | (761.02) | |||||
Negative figures in brackets.
Charts ten years each
CalciMedica Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| APRE Aprea Therapeutics, Inc. | $7.8M | — (loss-making) | — (loss-making) | −98.40% (below 0%: shrinking) | n/m | −5.22% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| SNGX Soligenix Inc. | $7.7M | — (loss-making) | — (loss-making) | −98.89% (below 0%: shrinking) | n/m | +37.83% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CURX Curanex Pharmaceuticals Inc | $7.6M | — (loss-making) | — | — | n/m | −272.32% (below 0%: shrinking) | — | 0.00% | Compare |
| MBRX Moleculin Biotech, Inc. | $7.6M | 0.0× | — | — | n/m | −19.26% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CALC CalciMedica Inc. | $7.4M | — (loss-making) | — | — | n/m | +31.42% (above 0%: growing) | 0.00% | 0.00% | |
| XCUR Exicure, Inc. | $7.3M | — (loss-making) | — (loss-making) | −80.51% (below 0%: shrinking) | n/m | +65.38% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SKYE Skye Bioscience, Inc. | $7.0M | — (loss-making) | — | −34.71% (below 0%: shrinking) | n/m | +34.84% (above 0%: growing) | 72.71% | 0.00% | Compare |
| BCLI Brainstorm Cell Therapeutics Inc. | $7.0M | — (loss-making) | — | — | n/m | +74.44% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR | $7.0M | — (loss-making) | — (loss-making) | −39.66% (below 0%: shrinking) | n/m | +5.08% (above 0%: growing) | (422.22%) | (2,437.96%) | Compare |
| Median of peers | $7.4M | — | — | −80.51% | — | +19.96% | 0.00% | 0.00% |
CalciMedica Inc. (CALC) key facts
- CalciMedica Inc. (CALC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, CALC traded at $1.07, a market capitalization of $7.4 million.
- Return on equity was −761.0% and debt-to-equity 1.67.